Summary
This prediction ended on 17.11.21 with a price of €49.63. The BUY prediction by Mori8 finished with a performance of 5.16%. Mori8 has a follow-up prediction for Bayer AG where he still thinks Bayer AG is a Buy. Mori8 has 50% into this predictionBayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Bayer AG | -2.266% | -2.266% | -57.017% |
iShares Core DAX® | -0.870% | -1.700% | 10.560% |
iShares Nasdaq 100 | -5.561% | -3.604% | 34.335% |
iShares Nikkei 225® | -6.138% | -7.732% | 16.215% |
iShares S&P 500 | -3.141% | -2.011% | 24.534% |
Comments by Mori8 for this prediction
In the thread Bayer AG diskutieren
https://www.boerse-daily.de/boersen-nachrichten/insight-bayer-long-weiter-im-rennen
Bayer Lifts Core EPS Outlook; Q3 Adj. EBITDA Beats Consensus
- (PLX AI) - Bayer Q3 EBIT EUR 530 million vs. estimate EUR 1,200 million after net special charges of EUR 694 million.
- • Q3 revenue EUR 9,781 million vs. estimate EUR 9,120 million
- • Q3 net income EUR 85 million
- • Outlook FY adjusted EBITDA margin 26%
- • Outlook FY free cash flow EUR -1,500 to -500 million (previously: between approximately minus 2 billion euros and minus 3 billion euros) as a portion of the settlement payments for the glyphosate litigations are now expected to be made in 2022 instead of 2021
- • Outlook FY revenue currency-adjusted EUR 44,000 million (unchanged)
- • Bayer lifts core eps outlook
- • Bayer Core earnings per share are now expected to come in at approximately 6.50 euros to 6.70 euros, up from 6.40 euros to 6.60 euros
- • Q3 adjusted EBITDA EUR 2,089 million vs. estimate EUR 1,940 million
In the thread Trading Bayer AG